| Oct. 15 |
Willy Roth, Boehringer-Ingelheim
Challenges in Drug Development - The DMPK Perspective?
Gerhard Gross, AstraZeneca
The Use of Drug Transporter Information in the New Drug Discovery and Development
in the Pharmaceutical Industry
Arto Urtti, University of Helsinki
Transporters in the Blood-retina-barrier: Current Status and Implications
Noriko Okudaira, Daiichi-Sankyo Company Ltd.
Risk Assessment of DDI Caused by MBI in the Drug Discovery Stage
Nanomi Mizuno and Takuro Niwa, Mitsubishi Pharma Corporation
Evaluation of Drug Transporters in Drug Discovery and Development
Masato Chiba, Banyu Pharmaceutical Co., Ltd.
A Novel Method for Evaluating Potential of Reactive Intermediates Formation
by using [35S]cysteine and [14C]cyanide as Nuclephilic Trapping Reagents
Toshihiko Ikeda, APDD
Metabolism-based Structural alert for Potential of Producing Chemically
Reactive Metabolites
|
|
